Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Bought by Eventide Asset Management LLC

Eventide Asset Management LLC grew its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 9.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 507,902 shares of the company's stock after acquiring an additional 45,803 shares during the quarter. Eventide Asset Management LLC owned about 0.78% of Kymera Therapeutics worth $24,039,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Comerica Bank increased its stake in Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company's stock valued at $134,000 after purchasing an additional 400 shares in the last quarter. Keudell Morrison Wealth Management increased its position in shares of Kymera Therapeutics by 7.2% in the 2nd quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company's stock valued at $212,000 after acquiring an additional 480 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock worth $114,000 after acquiring an additional 504 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Kymera Therapeutics by 8.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company's stock worth $534,000 after acquiring an additional 915 shares during the period. Finally, American International Group Inc. grew its stake in Kymera Therapeutics by 6.4% during the 1st quarter. American International Group Inc. now owns 20,095 shares of the company's stock valued at $808,000 after purchasing an additional 1,209 shares during the last quarter.

Kymera Therapeutics Stock Down 0.0 %

Shares of KYMR stock traded down $0.01 during trading hours on Friday, hitting $46.85. 184,881 shares of the company's stock were exchanged, compared to its average volume of 585,569. Kymera Therapeutics, Inc. has a fifty-two week low of $19.73 and a fifty-two week high of $53.27. The firm has a market cap of $3.03 billion, a P/E ratio of -20.02 and a beta of 2.21. The firm has a 50 day moving average of $46.82 and a two-hundred day moving average of $42.22.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $3.74 million during the quarter, compared to analysts' expectations of $10.34 million. During the same period in the prior year, the business posted ($0.90) earnings per share. The firm's revenue for the quarter was down 20.9% on a year-over-year basis. On average, equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Wells Fargo & Company raised their price objective on Kymera Therapeutics from $30.00 to $38.00 and gave the stock an "equal weight" rating in a research note on Monday, August 12th. UBS Group decreased their price objective on shares of Kymera Therapeutics from $80.00 to $74.00 and set a "buy" rating for the company in a research note on Monday, November 4th. Stephens assumed coverage on shares of Kymera Therapeutics in a report on Monday, November 18th. They issued an "overweight" rating and a $65.00 price objective on the stock. Leerink Partnrs raised shares of Kymera Therapeutics to a "strong-buy" rating in a report on Monday, September 9th. Finally, Oppenheimer upped their price target on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the company an "outperform" rating in a report on Friday, September 27th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $52.13.

Insider Buying and Selling

In related news, Director Pamela Esposito sold 13,500 shares of the business's stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 15.82% of the company's stock.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.